Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Depressive Disorder, Major, Inflammation
Interventions: Infliximab, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mild Cognitive Impairment, Metabolic Syndrome
Interventions: Dietary intervention; Behavioral
Lead sponsor: Bristlecone Health, Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Maple Grove, Minnesota

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo; Drug
Lead sponsor: Synthon BV; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions: somapacitan, somatropin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 23 Years to 79 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more

Conditions: Embryo Transfer
Interventions: Epelsiban, Placebo, Oxytocin, Ortho-Cylcen (21)® tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: End Stage Renal Disease, Anemia
Interventions: Roxadustat, Epoetin Alfa, Placebo; Drug · Other
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more

Conditions: Diabetic Peripheral Neuropathy, Nerve Pain
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 40 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Norfolk, Virginia

Conditions: Diabetes Mellitus, Type 1
Interventions: G-Pen Mini™ (glucagon injection), Glucose Tabs, Basal Insulin Reduction; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more

Conditions: Migraine Headache
Interventions: Stress, Fasting; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson's Disease
Interventions: Trans-Resveratrol; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Surgery
Interventions: Chlorhexidine Gluconate, Vehicle, DynaHex-2; Drug · Other
Lead sponsor: Medline Industries; Industry
Eligibility: 16 Years and older
Enrollment: 879 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Butte, Montana

Conditions: Chronic Kidney Diseases, Chronic Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Chronic Kidney Disease Stage 5, Hypertension
Interventions: Control-EDI, Intervention-EDI, Health coaching; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 85 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Ann Arbor, Michigan • Brighton, Michigan • Canton, Michigan + 6 more

Conditions: Pregnancy, Labor
Interventions: Misoprostol, Pitocin; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Perinatal Depression, Post Partum Depression, Depression, Postpartum, Depression
Interventions: Leuprolide Acetate 3.75 MG/ML, Estradiol 2 Mg tablet, Micronized progesterone; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 22 Years to 45 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: abatacept, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 20
States / cities: Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more

Conditions: Borderline Personality Disorder, Self-Injurious Behavior
Interventions: N-Acetylcysteine, placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Adult Idiopathic Generalized Osteoporosis
Interventions: Teriparatide, Saline Placebo; Drug
Lead sponsor: Elizabeth Shane; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Subarachnoid Hemorrhage, Aneurysmal
Interventions: tirofiban hydrochloride (AGGRASTAT®), MRI, Neurological Exam, Questionnaires, Vital Signs, Standard of Care Treatment; Drug · Diagnostic Test · Behavioral + 1 more
Lead sponsor: David Hasan; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Post-operative Pain
Interventions: Placebo, Pregabalin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Dry Eye
Interventions: NGF, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: Ghrelin, Saline; Drug · Other
Lead sponsor: Jenny Tong, MD, MPH; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Brain Edema, Brain Tumor
Interventions: hCRF, placebo hCRF; Drug
Lead sponsor: Celtic Pharma Development Services; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 27
States / cities: Phoenix, Arizona • Fresno, California • Newport Beach, California + 22 more

Conditions: Generalized Myasthenia Gravis, Myasthenia Gravis
Interventions: ALXN2050, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 17
States / cities: Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 14 more

Search by objective public record fields.

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

Efficacy and Safety of GTR in Comparison to Copaxone®

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy

The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Acute Stress Response in Migraine Sufferers

RESvEraTrol in Parkinson's Disease (RESET)

Preoperative CHG Cloth on Healthy Subjects

Controlling Hypertension Through Education and Coaching in Kidney Disease

Different Medications to Induce Labor

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD

Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

Preprandial Ghrelin Effect

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis